Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 40

1.

Ultrasonographic and Clinical Assessment of Peripheral Enthesitis in Patients with Psoriatic Arthritis, Psoriasis, and Fibromyalgia Syndrome: The ULISSE Study.

Macchioni P, Salvarani C, Possemato N, Gutierrez M, Grassi W, Gasparini S, Perricone C, Perrotta FM, Grembiale RD, Bruno C, Tripolino C, Govoni M, Ciancio G, Farina I, Ramonda R, Frallonardo P, Desiati F, Scarpa R, Costa L, Zabotti A, De Vita S, D'Attino RM, Gualberti G, Merolla R, di Luzio Paparatti U, Aldigeri R, Marchesoni A.

J Rheumatol. 2019 Mar 15. pii: jrheum.171411. doi: 10.3899/jrheum.171411. [Epub ahead of print]

2.

An Assessment of Hand Erosive Osteoarthritis: Correlation of Radiographic Severity with Clinical, Functional and Laboratory Findings.

Perrotta FM, Scriffignano S, De Socio A, Lubrano E.

Rheumatol Ther. 2019 Mar;6(1):125-133. doi: 10.1007/s40744-019-0145-7. Epub 2019 Feb 6.

3.

Analysis of potential determinants for a treat-to-target strategy in psoriatic arthritis patients from a real-world setting.

Lubrano E, Scriffignano S, De Socio A, Perrotta FM.

Clin Exp Rheumatol. 2018 Dec 20. [Epub ahead of print] No abstract available.

PMID:
30620284
4.

Role of comorbidities in spondyloarthritis including psoriatic arthritis.

Scriffignano S, Perrotta FM, De Socio A, Lubrano E.

Clin Rheumatol. 2019 Jan;38(1):3-10. doi: 10.1007/s10067-018-4332-7. Epub 2018 Oct 18.

PMID:
30338414
5.

Abatacept for the treatment of psoriatic arthritis.

Lubrano E, Scriffignano S, Perrotta FM.

Expert Rev Clin Immunol. 2018 Nov;14(11):899-905. doi: 10.1080/1744666X.2018.1527218. Epub 2018 Oct 12.

PMID:
30246575
6.

What Should Be the Primary Target of "Treat to Target" in Psoriatic Arthritis?

Coates LC, Lubrano E, Perrotta FM, Emery P, Conaghan PG, Helliwell PS.

J Rheumatol. 2019 Jan;46(1):38-42. doi: 10.3899/jrheum.180267. Epub 2018 Sep 15.

PMID:
30219765
7.

Validation of the Italian version of proposed GRAPPA flare questionnaire for patients with psoriatic arthritis.

Scriffignano S, Perrotta FM, De Socio A, Altobelli A, Sessa P, Scrivo R, Valesini G, Lubrano E.

Clin Exp Rheumatol. 2018 Aug 29. [Epub ahead of print]

PMID:
30183600
8.

Serum Sclerostin as a Possible Biomarker in Ankylosing Spondylitis: A Case-Control Study.

Perrotta FM, Ceccarelli F, Barbati C, Colasanti T, De Socio A, Scriffignano S, Alessandri C, Lubrano E.

J Immunol Res. 2018 May 2;2018:9101964. doi: 10.1155/2018/9101964. eCollection 2018.

9.

Residual disease activity in rheumatoid arthritis patients treated with subcutaneous biologic drugs that achieved remission or low disease activity: a longitudinal observational study.

Perrotta FM, De Socio A, Scriffignano S, Lubrano E.

Clin Rheumatol. 2018 Jun;37(6):1449-1455. doi: 10.1007/s10067-018-4038-x. Epub 2018 Feb 21.

PMID:
29468339
10.

The Sex Influence on Response to Tumor Necrosis Factor-α Inhibitors and Remission in Axial Spondyloarthritis.

Lubrano E, Perrotta FM, Manara M, D'Angelo S, Addimanda O, Ramonda R, Punzi L, Olivieri I, Salvarani C, Marchesoni A.

J Rheumatol. 2018 Feb;45(2):195-201. doi: 10.3899/jrheum.170666.

PMID:
29419448
11.

From clinical remission to residual disease activity in spondyloarthritis and its potential treatment implications.

Perrotta FM, De Socio A, Scriffignano S, Lubrano E.

Expert Rev Clin Immunol. 2018 Mar;14(3):207-213. doi: 10.1080/1744666X.2018.1429918. Epub 2018 Jan 25. Review.

PMID:
29338498
12.

The Sex Influence on Response to Tumor Necrosis Factor-α Inhibitors and Remission in Axial Spondyloarthritis.

Lubrano E, Perrotta FM, Manara M, D'Angelo S, Addimanda O, Ramonda R, Punzi L, Olivieri I, Salvarani C, Marchesoni A.

J Rheumatol. 2017 Nov 15. pii: jrheum.17666. doi: 10.3899/jrheum.17666. [Epub ahead of print]

PMID:
29142035
13.

Incidence of rheumatoid arthritis, psoriatic arthritis and polymyalgia rheumatica in an inland area of central Italy: results of the CAMPO-RHE study.

De Socio A, Perrotta FM, Grasso GM, Lubrano E.

Postgrad Med. 2018 Jan;130(1):137-141. doi: 10.1080/00325481.2018.1399774. Epub 2017 Nov 3.

PMID:
29088976
14.

Psoriatic arthritis: is it time to treat-to-target or target to treat?

Lubrano E, Perrotta FM.

Clin Rheumatol. 2017 Dec;36(12):2633-2635. doi: 10.1007/s10067-017-3885-1. Epub 2017 Oct 24.

PMID:
29067586
15.

Unmet Needs in Axial Spondyloarthritis.

Lubrano E, De Socio A, Perrotta FM.

Clin Rev Allergy Immunol. 2018 Dec;55(3):332-339. doi: 10.1007/s12016-017-8637-0. Review.

PMID:
28779298
16.

Elderly psoriatic arthritis patients on TNF-α blockers: results of an Italian multicenter study on minimal disease activity and drug discontinuation rate.

Costa L, Lubrano E, Ramonda R, Chimenti MS, Vezzù M, Perrotta FM, Del Puente A, Peluso R, Bottiglieri P, Lorenzin M, Sunzini F, Darda MA, Fiocco U, Perricone R, Punzi L, Scarpa R, Caso F.

Clin Rheumatol. 2017 Aug;36(8):1797-1802. doi: 10.1007/s10067-017-3697-3. Epub 2017 Jun 7.

PMID:
28589323
17.

Comparison of Composite Indices Tailored for Psoriatic Arthritis Treated with csDMARD and bDMARD: A Cross-sectional Analysis of a Longitudinal Cohort.

Lubrano E, De Socio A, Perrotta FM.

J Rheumatol. 2017 Aug;44(8):1159-1164. doi: 10.3899/jrheum.170112. Epub 2017 Jun 1.

PMID:
28572467
18.

Mesenchimal stem cells: a possible role in the pathogenesis and treatment of spondyloarthritis.

Perrotta FM, Guerra G, De Socio A, Scriffignano S, Lubrano E.

Reumatismo. 2017 May 22;69(1):1-8. doi: 10.4081/reumatismo.2017.976. Review.

19.

The role of IL-17 in the treatment of psoriatic arthritis.

Lubrano E, Perrotta FM.

Expert Rev Clin Immunol. 2017 Aug;13(8):815-821. doi: 10.1080/1744666X.2017.1327354. Epub 2017 May 16.

PMID:
28485176
20.

Chronic periaortitis with retroperitoneal fibrosis successfully treated with first line tocilizumab monotherapy: a case report.

Perrotta FM, Fici M, Guerra G, Brunese L, Salvarani C, Lubrano E.

Clin Exp Rheumatol. 2017 Mar-Apr;35 Suppl 103(1):226-227. Epub 2017 Apr 20. No abstract available.

PMID:
28466807
21.

Secukinumab for ankylosing spondylitis and psoriatic arthritis.

Lubrano E, Perrotta FM.

Ther Clin Risk Manag. 2016 Oct 21;12:1587-1592. eCollection 2016. Review.

22.

Assessment of semaphorin 3A and its role in bone remodelling in a group of ankylosing spondylitis patients.

Perrotta FM, Ceccarelli F, Barbati C, Colasanti T, Montepaone M, Alessandri C, Valesini G, Lubrano E.

Clin Exp Rheumatol. 2017 Mar-Apr;35(2):313-316. Epub 2016 Oct 26.

PMID:
27782869
23.

New approved drugs for psoriatic arthritis.

Perrotta FM, Lubrano E.

Reumatismo. 2016 Sep 9;68(2):57-64. doi: 10.4081/reumatismo.2016.873. Review. Italian.

24.

An ultrasonographic study of enthesis in early psoriatic arthritis patients naive to traditional and biologic DMARDs treatment.

Perrotta FM, Astorri D, Zappia M, Reginelli A, Brunese L, Lubrano E.

Rheumatol Int. 2016 Nov;36(11):1579-1583. Epub 2016 Sep 6.

PMID:
27600991
25.

Defining Low Disease Activity States in Psoriatic Arthritis Using Novel Composite Disease Instruments.

Lubrano E, Perrotta FM.

J Rheumatol. 2016 Sep;43(9):1765-6. doi: 10.3899/jrheum.160386. No abstract available.

PMID:
27587014
26.

Subcutaneous anti-TNF alfa induced sustained minimal disease activity and remission in psoriatic arthritis patients: a retrospective study.

Perrotta FM, Lubrano E.

Postgrad Med. 2016 Sep;128(7):693-6. doi: 10.1080/00325481.2016.1220809. Epub 2016 Aug 16.

PMID:
27494077
27.

Assessment of Response to Treatment, Remission, and Minimal Disease Activity in Axial Psoriatic Arthritis Treated with Tumor Necrosis Factor Inhibitors.

Lubrano E, Parsons WJ, Perrotta FM.

J Rheumatol. 2016 May;43(5):918-23. doi: 10.3899/jrheum.151404. Epub 2016 Mar 15.

PMID:
26980581
28.

Beyond TNF Inhibitors: New Pathways and Emerging Treatments for Psoriatic Arthritis.

Lubrano E, Perrotta FM.

Drugs. 2016 Apr;76(6):663-73. doi: 10.1007/s40265-016-0557-4. Review.

PMID:
26957495
29.

Minimal Disease Activity and Remission in Psoriatic Arthritis Patients Treated with Anti-TNF-α Drugs.

Perrotta FM, Marchesoni A, Lubrano E.

J Rheumatol. 2016 Feb;43(2):350-5. doi: 10.3899/jrheum.150805. Epub 2015 Dec 15.

PMID:
26669925
30.

Patient's Global Assessment as an Outcome Measure for Psoriatic Arthritis in Clinical Practice: A Surrogate for Measuring Low Disease Activity?

Lubrano E, Perrotta FM, Parsons WJ, Marchesoni A.

J Rheumatol. 2015 Dec;42(12):2332-8. doi: 10.3899/jrheum.150595. Epub 2015 Nov 1.

PMID:
26523033
31.

An overview of low disease activity and remission in psoriatic arthritis.

Lubrano E, Perrotta FM, Kavanaugh A.

Clin Exp Rheumatol. 2015 Sep-Oct;33(5 Suppl 93):S51-4. Epub 2015 Oct 15. Review.

PMID:
26470835
32.

Remission in nonradiographic axial spondyloarthritis treated with anti-tumor necrosis factor-α drugs: an Italian multicenter study.

Lubrano E, Perrotta FM, Marchesoni A, D'Angelo S, Ramonda R, Addimanda O, Olivieri I, Punzi L, Salvarani C.

J Rheumatol. 2015 Feb;42(2):258-63. doi: 10.3899/jrheum.140811. Epub 2014 Dec 15.

PMID:
25512483
33.

Predictive factors for partial remission according to the Ankylosing Spondylitis Assessment Study working group in patients with ankylosing spondylitis treated with anti-TNFα drugs.

Perrotta FM, Addimanda O, Ramonda R, D'Angelo S, Lubrano E, Marchesoni A, Olivieri I, Punzi L, Salvarani C, Spadaro A.

Reumatismo. 2014 Nov 6;66(3):208-14. doi: 10.4081/reumatismo.2014.756.

34.

Beyond the joint: Subclinical atherosclerosis in rheumatoid arthritis.

Scarno A, Perrotta FM, Cardini F, Carboni A, Annibali G, Lubrano E, Spadaro A.

World J Orthop. 2014 Jul 18;5(3):328-35. doi: 10.5312/wjo.v5.i3.328. eCollection 2014 Jul 18. Review.

35.

Rapid effectiveness of certolizumab pegol in non-radiographic axial spondyloarthritis.

Spadaro A, Scarno A, Carboni A, Perrotta FM, Catalano C, Lubrano E, Valesini G.

Reumatismo. 2013 Jul 24;65(3):134-7. doi: 10.4081/reumatismo.2013.134.

PMID:
23884030
36.

Assessment of subclinical atherosclerosis in ankylosing spondylitis: correlations with disease activity indices.

Perrotta FM, Scarno A, Carboni A, Bernardo V, Montepaone M, Lubrano E, Spadaro A.

Reumatismo. 2013 Jul 23;65(3):105-12. doi: 10.4081/reumatismo.2013.105.

PMID:
23884025
37.

Remission in ankylosing spondylitis treated with anti-TNF-α drugs: a national multicentre study.

Spadaro A, Lubrano E, Marchesoni A, D'Angelo S, Ramonda R, Addimanda O, Perrotta FM, Olivieri I, Punzi L, Salvarani C.

Rheumatology (Oxford). 2013 Oct;52(10):1914-9. doi: 10.1093/rheumatology/ket249. Epub 2013 Jul 22.

PMID:
23878312
38.

Power Doppler ultrasonographic evaluation of enthesitis in psoriatic arthritis. A multi-center study.

Iagnocco A, Spadaro A, Marchesoni A, Cauli A, De Lucia O, Gabba A, Takanen S, Montepaone M, Perrotta FM, D'Agostino MA, Mathieu A, Valesini G.

Joint Bone Spine. 2012 May;79(3):324-5. doi: 10.1016/j.jbspin.2011.10.005. Epub 2011 Nov 26. No abstract available.

39.

Clinical and ultrasonography assessment of peripheral enthesitis in ankylosing spondylitis.

Spadaro A, Iagnocco A, Perrotta FM, Modesti M, Scarno A, Valesini G.

Rheumatology (Oxford). 2011 Nov;50(11):2080-6. doi: 10.1093/rheumatology/ker284. Epub 2011 Aug 28.

40.

Validity, responsiveness and feasibility of an Italian version of the Canadian Occupational Performance Measure for patients with ankylosing spondylitis.

Spadaro A, Lubrano E, Massimiani MP, Gaia P, Perrotta FM, Parsons W, Ferrara N, Valesini G.

Clin Exp Rheumatol. 2010 Mar-Apr;28(2):215-22. Epub 2010 May 13.

PMID:
20483043

Supplemental Content

Loading ...
Support Center